title: Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations.
abstract: The agitation crisis in the awakening phase after traumatic brain injury (TBI) is one of the most difficult behavioral disorders to alleviate. Current treatment options are heterogeneous and may involve excessive sedation. Practice guidelines are required by professionals in charge of TBI patients. Few reviews were published but those are old and based on expert opinions. The purpose of this work is to propose evidence-based guidelines to treat the agitation crisis.
  
  
  METHODS
  The elaboration of these guidelines followed the procedure validated by the French health authority for good practice recommendations, close to the Prisma statement. Guidelines were elaborated on the basis of a systematic and critical review of the literature.
  
  
  RESULTS
  Twenty-eight articles concerning 376 patients were analyzed. Recommendations are: when faced with an agitation crisis, the management strategy implies to search for an underlying factor that should be treated such as pain, acute sepsis, and drug adverse effect (expert opinion). Physical restraints should be discarded when possible (expert opinion). Neuroleptic agent with a marketing authorization can be used in order to obtain a quick sedation so as to protect the patient from himself, closed ones or the healthcare team but the duration should be as short as possible (expert opinion). The efficacy of beta-blockers and antiepileptics with mood regulation effects like carbamazepine and valproate yield the most compelling evidence and should be preferably used when a background regimen is envisioned (grade B for beta-blocker and C for antiepileptics). Neuroleptics, antidepressants, benzodiazepines, buspirone may be prescribed but are considered second-line treatments (expert opinion).
  
  
  CONCLUSIONS
  This study provides a strategy for treating the agitation crisis based on scientific data and expert opinion. The level of evidence remains low and published data are often old. New studies are essential to validate results from previous studies and test new drugs and non-pharmaceutical therapies.
authors.affiliation: Service de médecine physique et de réadaptation, rééducation neurologique, hôpital Henry-Gabrielle, CHU de Lyon, 20, route de Vourles, 69230 Saint-Genis-Laval, France; Équipe Impact, Inserm, U1028, CNRS, UMR5292, centre de recherche en neuroscience de Lyon (CRNL), Lyon, France. Electronic address: jacques.luaute@chu-lyon.fr.
authors.forename: Jacques
authors.initials: J
authors.lastname: Luauté
authors.affiliation: Service de médecine physique et réadaptation, rééducation neurologique, hôpital René-Sabran, CHU de Lyon, 83400 Hyères, France.
authors.forename: David
authors.initials: D
authors.lastname: Plantier
authors.affiliation: Cabinet de médecine physique et de réadaptation, 55, rue Eugène-Jacquet, 33000 Bordeaux, France; UEROS, service de médecine physique et de réadaptation, université Bordeaux-Segalen, CHU Pellegrin, 33076 Bordeaux cedex, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Wiart
authors.affiliation: Service de médecine physique et de réadaptation, rééducation neurologique, hôpital Henry-Gabrielle, CHU de Lyon, 20, route de Vourles, 69230 Saint-Genis-Laval, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Tell
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000374:Aggression; D000547:Amantadine / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D001930:Brain Injuries / Q000523:psychology*; D002065:Buspirone / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use; D011595:Psychomotor Agitation / Q000209:etiology / Q000628:therapy*; D012149:Restraint, Physical
chemical_list: D000319:Adrenergic beta-Antagonists; D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D015259:Dopamine Agents; D001569:Benzodiazepines; D008774:Methylphenidate; D000547:Amantadine; D002065:Buspirone
keywords: Aggressive behaviour; Agitation crisis; Guideline; Traumatic brain injury; Treatment strategy